Occult HBV infection among a cohort of Nigerian adults

Journal of Infection in Developing Countries

Volumn 3, Issue 6, 2009, Pages 442-446

  Ola, Samuel O ^a   Otegbayo, Jesse A ^a   Odaibo, Georgina N ^b   Olaleye, David O ^b   Olubuyide, Itunu O ^a   Summerton, Christopher B ^c   Bamgboye, Elijah A ^b  

^a UNIVERSITY OF IBADAN   (Nigeria)

^b UNIVERSITY OF IBADAN   (Nigeria)

^c TRAFFORD GENERAL HOSPITAL   (United Kingdom)

Author keywords

HCV; Nigerians; Occult HBV infection

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NIGERIA; SERODIAGNOSIS; VIRUS DETECTION;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 73249124121     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.415     Document Type: Article

References (16)

1. WHO/CDS/CSR/LYO/2002.2:Hepatitis B. Available: http://www.who.int/csr/ disease/hepatitis/HepatitisB-whocdscsrlyo2002-2.pdf Accessed May 27, 2008.
2. Ola SO, Anomneze EE, Chukwuani CM, Ojo OS, Ndububa DA, Onyenkwe B, Nasidi A (2000) Interferon alfa-2a (Roferon-A) in the management of Chronic Hepatitis B infection: Results of an open prospective study in Nigerian patients. West Afri. Med. J. 19: 259-264.
3. Odemuyiwa SO, Mulders MN, Oyedele OI, Ola SO, Odaibo GN, Olaleye DO, Muller CP (2001) Phylogenetic analysis of new Hepatitis B virus isolates from Nigeria support endemicity of Genotype E in West Africa. J Med Virol 65: 463-469.
4. Ola SO, Otegbayo JA, Odaibo GN, Olaleye OD, Olubuyide IO (2002) Serum hepatitis C virus and hepatitis B surface antigenaemia in Nigerian patients with acute icteric hepatitis. West Afr J Med 21: 215-217.
5. Ajayi AO, Komolafe AO, Ajumobi K (2007) Sero-prevalence of hepatitis B surface antigenaemia among health care workers in a Nigerian tertiary health institution. Nig J Clin Pract 10: 287-289.
6. Czaja Albert J (1993) Chronic Active Hepatitis: The Challenge for a New Nomenclature. Ann Intern Med 119: 510-517.
7. Behzad-Behbahani A, Mafi-Nejad A, Tabei SZ, Lankarani KB, Torab A, Moaddeb A (2006) Anti-HBc & HBV-DNA detection in blood donors negative for hepatitis B virus surface antigen in reducing risk of transfusion associated HBV infection. Indian J Med Res123: 37-42.
8. Olubuyide IO, Ola SO, Aliyu B, Dosumu OO, Arotiba JT, Olaleye OD, Odaibo GN, Odemuyiwa SO, Olawuyi F (1997) Hepatitis B and C in doctors and dentists in Nigeria Quart. J Med 90: 417-422.
9. Candotti D, Opare-Sem O, Rezvan H, Sarkodie F, Allain JP (2006) Molecular and serological characterization of hepatitis B virus in deferred Ghanaian blood donors with and without elevated alanine aminotransferase. J Viral Hepat 13: 715-724.
10. Hasegawa I, Tanaka Y, Kurbanov F, Yoshihara N, El-Gohary A, Lyamuya E, Matee M, Magessa P, Fujiwara K, Ozasa A, Sugauchi F, Orito E, Ueda R, Mizokami M (2006) Molecular epidemiology of hepatitis B virus in the United Republic of Tanzania. J Med Virol 78: 1035-1042.
11. Chemin I, Trepo C (2005) Clinical Impact of occult HBV infection. J Clinical Virol 34: Suppl.1: S15-S21.
12. Allain JP (2004) Occult hepatitis B virus infection: implications in transfusion. Vox Sang 86: 83-91.
13. Arraes LC, Ximenes R, Andrieu JM, Lu W, Barreto S, Pereira LM, Castelo A (2003) The biological meaning of anti-HBc positive result in blood donors: relation to HBV-DNA and to other serological markers. Rev Inst Med Trop Sao Paulo 45: 137-140.
14. Gish RG, Locarnini SA (2006) Chronic hepatitis B: current testing strategies. Clin Gastroenterol Hepatol 4: 666-676.
15. Han SH (2006) Natural course, therapeutic options and economic evaluation of therapies for chronic hepatic B. Drugs 66: 1831-1851.
16. Raimondo G, Pollicino T, Cacciola I, Squadrito G (2007) Occult hepatitis B virus infection. J Hepatol 46: 160-170.